A Phase IIa Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Bimatoprost in the Treatment of Migraine
Latest Information Update: 05 Apr 2021
Price :
$35 *
At a glance
- Drugs Bimatoprost (Primary)
- Indications Migraine
- Focus Therapeutic Use
- 25 Apr 2019 Planned End Date changed from 1 Dec 2018 to 30 Jun 2018.
- 25 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 13 Aug 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.